BM Absorbance (490 nm) ± SEM % viability Fold change, with respect to Control TG TG-F Control 1.44 ± 0.51 100.00       TG24 1.25 ± 0.16 81.33 (-) 1.15     TG24F 1.33 ± 0.49 93.29   (+) 1.06   TG24MF 1.35 ± 0.05 94.31   (+) 1.08 (+) 1.02 TG48 1.16 ± 0.22 76.42 (-) 1.24     TG48F 1.37 ± 0.23 94.36   (+) 1.18   TG48MF 1.27 ± 0.32 83.85   (+) 1.09 (-) 1.08 TG72 1.05 ± 0.24 61.06 (-) 1.37     TG72F 1.16 ± 0.23 85.08   (+) 1.10   TG72MF 1.36 ± 0.07 87.31   (+) 1.29 (+) 1.17 TG96 0.97 ± 0.07 58.66 (-) 1.49     TG96F 1.27 ± 0.06 83.11   (+) 1.31*   TG96MF 1.19 ± 0.10 79.33   (+) 1.22 (-) 1.07 (#: p<0.05 versus Control; *: p<0.05 versus TG; *: p<0.05 versus TG-F)

Table 10: Fold changes in viability of cells in bone marrow, assayed by MTS reagent, at 492 nm. With fisetin, there is a 1.06 fold increase in cell viability after 24 h, a 1.18 fold increase after 48 h, a 1.10 fold increase after 72 h, and a 1.31 fold (p<0.05) increase after 96 h. With MCN+fisetin, there is a 1.08 fold after 24 h, a 1.09 fold increase after 48 h, a 1.29 fold increase after 72 h and a 1.22 fold increase after 96 h.